Search results for "PHARMACOLOGY"

showing 10 items of 8885 documents

H89 Treatment Reduces Intestinal Inflammation and Candida albicans Overgrowth in Mice

2020

Deregulation of the dynamic crosstalk between the gut microbiota, intestinal epithelial cells, and immune cells is critically involved in the development of inflammatory bowel disease and the overgrowth of opportunistic pathogens, including the human opportunistic fungus Candida albicans. In the present study, we assessed the effect of N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H89), a protein kinase A inhibitor, on the migration of macrophages to C. albicans through dextran sulphate sodium (DSS)-challenged Caco-2 cells. We also investigated the impact of H89 on intestinal inflammation and C. albicans clearance from the gut, and determined the diversity of the gut microbio…

0301 basic medicineMicrobiology (medical)<i>Lactobacillus johnsonii</i>colitisH89030106 microbiologyInflammationGut floraMicrobiologydigestive systemArticleMicrobiology03 medical and health sciences<i>Enterococcus faecalis</i>Immune system[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesVirologyCandida albicansmedicineEscherichia coliEnterococcus faecalismicrobiotaColitisCandida albicanslcsh:QH301-705.5Lactobacillus johnsoniiLactobacillus johnsoniiDSSH89;Candida albicans;Escherichia coli;Enterococcus faecalis;Lactobacillus johnsonii;microbiota;DSS;colitis;protein kinase AInnate immune systembiology<i>Escherichia coli</i>[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.diseasebiology.organism_classificationCorpus albicans3. Good health<i>Candida albicans</i>030104 developmental biologylcsh:Biology (General)[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacologyprotein kinase Amedicine.symptomMicroorganisms
researchProduct

Antibacterial Activity of Propolis Extracts from the Central Region of Romania against Neisseria gonorrhoeae

2021

(1) Background: Sexually transmitted infections (STIs) are among the most common infections worldwide, many of these being caused by Neisseria gonorrhoeae (NG). Increased antimicrobial NG resistance has been reported in recent decades, highlighting the need for new sources of natural compounds with valuable antimicrobial activity. This study aims to determine the effect of propolis extracts on NG strains, including antibiotic-resistant strains. (2) Methods: First void urine samples from presumed positive STI subjects were harvested. DNA was extracted, purified, and amplified via PCR for the simultaneous detection of 6 STIs. The presence of the dcmH, gyrA, and parC genes was checked in the D…

0301 basic medicineMicrobiology (medical)<i>Neisseria gonorrhoeae</i>030106 microbiologyRM1-950Biologymedicine.disease_cause030226 pharmacology & pharmacyBiochemistryMicrobiologyCentral regionArticleMicrobiology03 medical and health sciences0302 clinical medicineantibacterial activitymedicinePharmacology (medical)Statistical analysisciprofloxacin resistanceGeneral Pharmacology Toxicology and PharmaceuticsPropolisAntimicrobialIn vitroNeisseria gonorrhoeaeCiprofloxacinInfectious DiseasesNeisseria gonorrhoeaeTherapeutics. PharmacologyAntibacterial activitypropolis extractsmedicine.drugAntibiotics
researchProduct

In vitro activity of anidulafungin in combination with amphotericin B or voriconazole against biofilms of five Candida species

2016

Objectives: To evaluate the in vitro activity of anidulafungin combined with amphotericin B or voriconazole against Candida spp. biofilms. Methods: Four Candida albicans, four Candida tropicalis, four Candida glabrata, two Candida parapsilosis and two Candida orthopsilosis blood isolates were tested by the microdilution chequerboard method combined with the XTT metabolic assay. Biofilm MIC was defined as the lowest concentration producing 50% metabolic inhibition with respect to control (BMIC50). Concentrations in the combinations ranged from 1/8xBMIC(50) to 4xBMIC(50) found for each antifungal tested alone. Results: Anidulafungin plus amphotericin B acted synergistically against C. albican…

0301 basic medicineMicrobiology (medical)Antifungal Agents030106 microbiologyMicrobial Sensitivity TestsCandida parapsilosisAnidulafunginMicrobiologyCandida tropicalis03 medical and health sciencesEchinocandinsAmphotericin BAmphotericin BmedicineHumansPharmacology (medical)Candida albicansCandidaPharmacologyVoriconazolebiologyCandida glabrataChemistryCandidemiaDrug Synergismbiology.organism_classificationbacterial infections and mycosesCorpus albicansInfectious DiseasesBiofilmsAnidulafunginVoriconazolemedicine.drug
researchProduct

(1,3)-β-d-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study.

2016

OBJECTIVES To determine the effects of a strategy that uses serum (1,3)-β-d-glucan (BDG) results for antifungal treatment of ICU patients at high risk of invasive candidiasis. PATIENTS AND METHODS Adult patients admitted to the ICU from January 2012 to June 2014 were included if they exhibited sepsis at the time of BDG testing and they met Candida score components ≥3. A retrospective analysis of collected data was performed. RESULTS In total, 198 patients were studied. Of 63 BDG-positive patients, 47 with candidaemia and 16 with probable Candida infection, all [31.8% (63/198)] received antifungal therapy. Of 135 BDG-negative patients, 110 [55.5% (110/198)] did not receive antifungal therapy…

0301 basic medicineMicrobiology (medical)AntifungalAdultMalemedicine.medical_specialtyAntifungal AgentsAntigens Fungalbeta-GlucansLetterAdolescentMedicine (all); Pharmacology; Infectious Diseases; Pharmacology (medical)medicine.drug_classCritical Illness030106 microbiologyAntifungal drugSettore MED/17 - MALATTIE INFETTIVESettore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICAlaw.inventionSepsis03 medical and health sciencesYoung AdultlawInternal medicineSepsismedicineHumansPharmacology (medical)Candidiasis InvasiveMedical prescriptionYoung adultCandidaAgedRetrospective StudiesPharmacologyAged 80 and overbusiness.industryMedicine (all)Retrospective cohort studyMiddle Agedmedicine.diseaseIntensive care unitSurgeryInfectious DiseasesObservational studyFemaleProteoglycansbusinessThe Journal of antimicrobial chemotherapy
researchProduct

In Vitro Antimicrobial Activity of Frankincense Oils from Boswellia sacra Grown in Different Locations of the Dhofar Region (Oman)

2020

Frankincense essential oils from Boswellia sacra have been commonly used to treat microbial infections from as early as the 11th century. The main feature of the plant is its gum resin, from which it is possible to obtain essential oils. In the present study, we focused on the comparative study of the oils extracted from the resins of three different Boswellia sacra cultivars (Najdi, Sahli and Houjri). From each of frankincense resin three successive essential oil samples (Grade 1, Grade 2, Grade 3) were obtained. Houjri gum resin gave the lowest percentage (5%) of total essential oil content but showed the maximum number of volatile components in all three grades. Najdi Grade 2 essential o…

0301 basic medicineMicrobiology (medical)Candida albicanStaphylococcus aureusmedicine.disease_causeSettore BIO/19 - Microbiologia Generale01 natural sciencesBiochemistryMicrobiologylaw.invention03 medical and health sciencesPropionibacterium acnesMinimum inhibitory concentrationlawPropionibacterium acneCandida albicansmedicinePharmacology (medical)Propionibacterium acnesGeneral Pharmacology Toxicology and PharmaceuticsCandida albicansEssential oilGC/MS analysiBoswellia sacraantimicrobial activitybiologyTraditional medicine010405 organic chemistrylcsh:RM1-950Malassezia furfurFrankincensebiology.organism_classificationAntimicrobial0104 chemical sciencesBoswellia sacralcsh:Therapeutics. Pharmacology030104 developmental biologyInfectious DiseasesStaphylococcus aureusPseudomonas aeruginosaStaphylococcus aureuGC/MS analysisfrankincense essential oilAntibiotics
researchProduct

Identification of New Antimicrobial Peptides from Mediterranean Medical Plant Charybdis pancration (Steinh.) Speta

2020

The present work was designed to identify and characterize novel antimicrobial peptides (AMPs) from Charybdis pancration (Steinh.) Speta, previously named Urginea maritima, is a Mediterranean plant, well-known for its biological properties in traditional medicine. Polypeptide-enriched extracts from different parts of the plant (roots, leaves and bulb), never studied before, were tested against two relevant pathogens, Staphylococcus aureus and Pseudomonas aeruginosa. With the aim of identifying novel natural AMPs, peptide fraction displaying antimicrobial activity (the bulb) that showed minimum inhibitory concentration (MICs) equal to 30 &micro

0301 basic medicineMicrobiology (medical)Charybdis030106 microbiologyAntimicrobial peptides) SpetaSettore BIO/05 - ZoologiatemporinPeptidemedicine.disease_causeSettore BIO/19 - Microbiologia GeneraleBiochemistryMicrobiologyMicrobiologyantibiotic resistant strains03 medical and health sciencesMinimum inhibitory concentrationAntibiotic resistancemedicinePharmacology (medical)high-resolution mass spectrometryGeneral Pharmacology Toxicology and Pharmaceuticsplant defensinschemistry.chemical_classificationbiologyPseudomonas aeruginosaantimicrobial peptides from plantCharybdis pancration (Steinh.) SpetaSettore BIO/02 - Botanica Sistematicalcsh:RM1-950temporinsbiology.organism_classificationAntimicrobialplant defensinmolecular dynamicslcsh:Therapeutics. Pharmacology030104 developmental biologyInfectious DiseaseschemistryStaphylococcus aureusCharybdis pancration (Steinhantimicrobial peptides from plants<i>Charybdis pancration</i> (Steinh.) Spetaantibiotic resistant strainAntibiotics
researchProduct

Early adjustment of empirical antibiotic therapy of bloodstream infections on the basis of direct identification of bacteria by matrix-assisted laser…

2020

Abstract Introduction To assess the potential added value of rapid MALDI-TOF MS-based identification of bacteria in positive blood cultures to the information provided by Gram staining for adequate empirical antibiotic treatment adjustments in patients with bloodstream infections (BSI). Methods We conducted a retrospective, single-center, pre-post quasi-experimental study. In the pre-MALDI-TOF MS phase of the study antibiotic adjustments were made on the basis of Gram stain results, whereas in the MALDI-TOF MS phase they were based on information provided by Gram staining and MALDI-TOF MS results. No antimicrobial stewardship program for BSI was in place within the study period. Antibiotic …

0301 basic medicineMicrobiology (medical)EnterobacterialesBacillimedicine.medical_specialtymedicine.drug_class030106 microbiologyAntibioticsBacteremialaw.invention03 medical and health sciences0302 clinical medicinelawSepsisInternal medicinemedicineHumansAntimicrobial stewardshipPharmacology (medical)Blood culture030212 general & internal medicineRetrospective StudiesBacteriaStaining and Labelingbiologymedicine.diagnostic_testbusiness.industryLasersbiology.organism_classificationmedicine.diseaseAnti-Bacterial AgentsInfectious DiseasesGram stainingSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationBacteremiabusinessBacteriaJournal of Infection and Chemotherapy
researchProduct

Antibiotic Resistance of Gram-Negative Bacteria from Wild Captured Loggerhead Sea Turtles

2020

Sea turtles have been proposed as health indicators of marine habitats and carriers of antibiotic-resistant bacterial strains, for their longevity and migratory lifestyle. Up to now, a few studies evaluated the antibacterial resistant flora of Mediterranean loggerhead sea turtles (Caretta caretta) and most of them were carried out on stranded or recovered animals. In this study, the isolation and the antibiotic resistance profile of 90 Gram negative bacteria from cloacal swabs of 33 Mediterranean wild captured loggerhead sea turtles are described. Among sea turtles found in their foraging sites, 23 were in good health and 10 needed recovery for different health problems (hereafter named wea…

0301 basic medicineMicrobiology (medical)Gram-negative bacteriaantibiotic resistanceSettore BIO/07030106 microbiologyZoologyBiochemistryMicrobiologyArticlebacterial ecology03 medical and health sciencesMarine bacteriophageMediterranean seaAntibiotic resistanceVibrionaceaeCaretta caretta; Mediterranean Sea; antibiotic resistance; bacterial ecology; feeding; marine bacteria; marine habitats; marine microbial ecologyAmpicillinmarine microbial ecologyMediterranean SeamedicinePharmacology (medical)General Pharmacology Toxicology and PharmaceuticsCaretta carettabiologySulfamethoxazolelcsh:RM1-950biology.organism_classification030104 developmental biologyInfectious Diseaseslcsh:Therapeutics. Pharmacologymarine bacteriamarine habitatmarine habitatsBacteria<i>Caretta caretta</i>feedingmedicine.drugAntibiotics
researchProduct

Draft genome sequence and biofilm production of a carbapenemase-producing Klebsiella pneumoniae (KpR405) sequence type 405 strain isolated in Italy

2021

Rapid identification and characterization of multidrug-resistant Klebsiella pneumoniae strains is essential to diagnose severe infections in patients. In clinical routine practice, K. pneumoniae is frequently identified and characterized for outbreak investigation. Pulsed-field gel electrophoresis or multilocus sequence typing could be used, but, unfortunately, these methods are time-consuming, laborious, expensive, and do not provide any information about the presence of resistance and virulence genes. In recent years, the decreasing cost of next-generation sequencing and its easy use have led to it being considered a useful method, not only for outbreak surveillance but also for rapid ide…

0301 basic medicineMicrobiology (medical)Klebsiella pneumoniae<i>Klebsiella pneumoniae</i>030106 microbiologyVirulenceRM1-950BiochemistryMicrobiologyMicrobiologyCarbapenemase03 medical and health sciencesPharmacology (medical)General Pharmacology Toxicology and PharmaceuticsPathogenWhole genome sequencingbiologyBiofilmBiofilmOutbreakST405biology.organism_classificationKlebsiella pneumoniae030104 developmental biologyInfectious DiseasesMultilocus sequence typingTherapeutics. PharmacologyBacteria
researchProduct

Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on …

2017

Abstract Introduction The study objective was to evaluate the efficacy of different dosages of caspofungin in the treatment of invasive candidiasis and aspergillosis, in relation to the probability of pharmacokinetic/pharmacodynamic (PK/PD) target attainment, using modelling and Monte Carlo simulations in critically ill adult patients on continuous haemodiafiltration. Methods Critically ill adult patients on continuous venovenous haemodiafiltration treated with caspofungin were analysed. A population PK model was developed. Four caspofungin dosing regimens were simulated: the licensed regimen, 70 mg/day, 100 mg/day or 200 mg/day. A PK/PD target was defined as the ratio between the area unde…

0301 basic medicineMicrobiology (medical)MaleAntifungal AgentsCandida parapsilosisCritical Illness030106 microbiologyPopulationCandida glabrataHemodiafiltrationMicrobial Sensitivity TestsPharmacologyAspergillosis03 medical and health scienceschemistry.chemical_compoundEchinocandinsLipopeptides0302 clinical medicinePharmacokineticsCaspofunginCandida albicansMedicineHumansPharmacology (medical)Candidiasis Invasive030212 general & internal medicineDosingeducationAgedAged 80 and overInvasive Pulmonary Aspergillosiseducation.field_of_studyMaintenance dosebusiness.industryCandidiasisGeneral MedicineMiddle Agedmedicine.diseaseRegimenInfectious DiseasesAspergilluschemistryPharmacodynamicsFemaleCaspofunginbusinessInternational journal of antimicrobial agents
researchProduct